Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 7/20 | 0.64 |
| ▸ | CYP2A6 | P11509 | 4/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.42 |
| ▸ | BACE1 | P56817 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | AR | P10275 | 1/20 | 0.40 |
| ▸ | CCR1 | P32246 | 1/20 | 0.39 |
| ▸ | CCR8 | P51685 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | HPRT1 | P00492 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | TRPM4 | Q8TD43 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20967457 | 0.78 | CYP1A2 (0.42) | CYP1A2CYP2A6ALDH1A1BACE1KDM4E | |
| SCHEMBL29352143 | 0.78 | CYP1A2 (1.00) | CYP1A2CYP2A6ALDH1A1HSD17B10HPGD | |
| SCHEMBL598829 | 0.78 | CYP1A2 (1.00) | CYP1A2CYP2A6ALDH1A1HSD17B10HPGD | |
| SCHEMBL15352228 | 0.77 | CYP1A2 (0.63) | CYP1A2CYP2A6ALDH1A1HSD17B10HPGD | |
| SCHEMBL1402233 | 0.76 | CYP1A2 (0.64) | CYP1A2CYP2A6ALDH1A1HSD17B10HPGD | |
| SCHEMBL20967458 | 0.76 | CYP1A2 (0.46) | CYP1A2CYP2A6ALDH1A1HSD17B10HPGD | |
| Ammonia Solution, Strong SCHEMBL27919233 | 0.76 | CYP1A2 (0.95) | CYP1A2CYP2A6ALDH1A1HSD17B10HPGD | |
| SCHEMBL599191 | 0.75 | CYP1A2 (0.62) | CYP1A2CYP2A6ALDH1A1HSD17B10HPGD | |
| SCHEMBL30366289 | 0.75 | HPRT1 (0.52) | CYP1A2CYP2A6ALDH1A1HSD17B10HPGD | |
| SCHEMBL3368401 | 0.75 | HPRT1 (0.52) | CYP1A2CYP2A6ALDH1A1HSD17B10HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023205719-A1 | KRAS G12D MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2023-10-26 | — | — | WO | disclosed |
| US-20230303586-A1 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC (US) | 2023-09-28 | — | — | US | disclosed |
| US-20230303586-A1 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC (US) | 2023-09-28 | — | — | US | disclosed |
| EP-4209492-A1 | COMPOUND FOR TREATING THROMBOTIC DISEASES | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2023-07-12 | — | — | EP | disclosed |
| US-11566016-B2 | MAP kinase modulators and uses thereof | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-01-31 | — | — | US | disclosed |
| US-11251376-B2 | Heterocyclic compound and organic light-emitting device including the same | SAMSUNG DISPLAY CO., LTD. (KR) | 2022-02-15 | — | — | US | disclosed |
| US-20220009905-A1 | MAP KINASE MODULATORS AND USES THEREOF | NORTHWESTERN UNIVERSITY | 2022-01-13 | — | — | US | disclosed |
| US-11149020-B2 | MAP kinase modulators and uses thereof | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2021-10-19 | — | — | US | disclosed |
| US-11133473-B2 | Condensed cyclic compound and organic light-emitting device including the same | SAMSUNG DISPLAY CO., LTD. (KR) | 2021-09-28 | — | — | US | disclosed |
| EP-3842424-A1 | MAP KINASE MODULATORS AND USES THEREOF IN THE TRETAMENT OF TAUOPATHIES | The Trustees of Columbia University in the City of New York (US) | 2021-06-30 | — | — | EP | disclosed |
| WO-2002057264-A1 | PYRROLE DERIVATES FOR TREATING CYTOKINE MEDIATED DISEASES | SANKYO COMPANY LIMITED (JP) | 2002-07-25 | — | — | WO | disclosed |
| EP-1070711-A2 | Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses | Sankyo Company Limited (JP) | 2001-01-24 | — | — | EP | disclosed |
| US-4207241-A | ANALGESICS, ANTIPYRETICS, ANTIINFLAMMATORY AGENTS AND ANTIPRURITIC AGENTS | SYNTEX CORPORATION (US) | 1980-06-10 | — | — | US | disclosed |
| US-4097674-A | ANTIINFLAMMATORY, ANTIPYRETIC, ANTIPRURITIC AGENTS, ANALGESICS | SYNTEX CORPORATION (US) | 1978-06-27 | — | — | US | disclosed |
| US-4051233-A | ANTIINFLAMMATORY, ANALGESIC, ANTIPYRETIC, ANTIPRURITIC | SYNTEX CORPORATION (US) | 1977-09-27 | — | — | US | disclosed |
| US-4001301-A | ANTIINFLAMMATORY AGENTS, ANALGESICS, ANTIPYRETICS, ANTI-PRURITIC | SYNTEX CORPORATION (PM) | 1977-01-04 | — | — | US | disclosed |
| US-3998966-A | Anti-inflammatory, analgesic, anti-pyretic and anti-pruritic 6-substituted 2-naphthyl acetic acid derivative-containing compositions and methods of use thereof | SYNTEX CORPORATION (PM) | 1976-12-21 | — | — | US | disclosed |
| US-3980699-A | ANTIINFLAMMATORY, ANALGESICS, ANTIPYRETIC, ANTIPRURITIC | SYNTEX CORPORATION (PM) | 1976-09-14 | — | — | US | disclosed |
| US-3978124-A | ANALGESIC, ANTIPYRETIC | SYNTEX CORPORATION (PM) | 1976-08-31 | — | — | US | disclosed |
| US-3978116-A | ANALGESIC, ANTIPYRETIC | SYNTEX CORPORATION (PM) | 1976-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11133473-B2 | Condensed cyclic compound and organic light-emitting device including the same | C1S, C1R, CCNA1 | CYP1A2 985/4885CYP2A6 1803/4885ALDH1A1 1601/4885 |
| US-11251376-B2 | Heterocyclic compound and organic light-emitting device including the same | LAGE3, DDT, AOC2 | CYP1A2 30/4885CYP2A6 897/4885ALDH1A1 57/4885 |
| US-11566016-B2 | MAP kinase modulators and uses thereof | MAPK1, MAP3K1, MAP3K2 | CYP1A2 4173/4885CYP2A6 4660/4885ALDH1A1 2033/4885 |
| US-11149020-B2 | MAP kinase modulators and uses thereof | MAPK1, MAP3K1, MAP3K2 | CYP1A2 4173/4885CYP2A6 4660/4885ALDH1A1 2033/4885 |
| US-20230303586-A1 | INHIBITORS OF KRAS G12C | KRAS, NRAS, HRAS | CYP1A2 3408/4885CYP2A6 3163/4885ALDH1A1 4178/4885 |
| US-20220009905-A1 | MAP KINASE MODULATORS AND USES THEREOF | MAPK1, MAP3K1, MAP3K2 | CYP1A2 4173/4885CYP2A6 4660/4885ALDH1A1 2033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.